CiRA, Kyoto University and Astellas Pharma Enter into Joint Research Agreement
Tuesday, April 11, 2023
The Centre for iPS Cell Research and Application, Kyoto University and Astellas Pharma entered into the second phase of a joint research agreement to further promote the utilization of differentiated cells and tissues derived from human induced pluripotent stem cells (iPS cells) and to create innovative medical solutions.
The joint research agreement with Astellas, which includes state-of-the-art core technology for drug discovery, will be of critical importance to generating new possibilities of drug discovery using iPS cell technology. This joint research, will contribute to drug discovery and development of treatments for various diseases as soon as possible.
This collaboration between CiRA, with expertise in iPS cells and cell therapy, and Astellas, with proven expertise in drug development, will bring even greater VALUE to patients.
CiRA and Astellas will further promote the use of iPS cell-derived differentiated cells and tissues to create innovative medical solutions to offer new treatment options for patients, thereby contributing to the treatment of diseases with high unmet medical needs.
